|View printer-friendly version|
|May 23, 2002 4:15 p.m.|
|Teva Announces Federal Judge Invalidates Remaining Augmentin Patents|
Jerusalem, Israel, May 23, 2002 - Teva Pharmaceutical Industries, Ltd. (Nasdaq: TEVA) announced that a federal judge has ruled today in its favor, invalidating the three remaining GlaxoSmithKline patents that were being challenged by generic manufacturers, otherwise due to expire by December 24, 2002, covering the antibiotic Augmentin®. The ruling follows two earlier decisions by the same court on March 13, 2002 and December 14, 2001 that invalidated four GlaxoSmithKline patents otherwise scheduled to expire in 2017 and 2018. The most recent ruling was issued by the federal judge from the bench immediately following the conclusion of the trial.